Researchers to Present Nine Studies on Soliris in Patients with PNH and aHUS at EHA Congress on June9-12

Alexion Pharmaceuticals ALXN today announced that researchers will present data relating to Soliris at the 16th Congress of the European Hematology Association, to be held June 9-12, 2011, in London. Findings will be presented from studies of Soliris as a treatment for patients with paroxysmal nocturnal hemoglobinuria as well as a potential treatment for patients with atypical hemolytic uremic syndrome. Abstracts summarizing these presentations were published today on the EHA website and can be accessed using the links below. Soliris is approved for the treatment of patients with PNH in more than 35 countries worldwide. Alexion has submitted marketing applications to the U.S. Food and Drug Administration and the European Medicines Agency (EMA) for Soliris as a treatment for patients with aHUS.